Tissue microarray analysis of ezrin, KBA.62, CD166, nestin, and p-Akt in melanoma versus Banal and atypical nevi, and nonmelanocytic lesions

American Journal of Dermatopathology

Volumn 33, Issue 7, 2011, Pages 663-668

  Shanesmith, Rebecca P ^a   Smart, Chandra ^b   Cassarino, David S ^c  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c KAISER PERMANENTE   (United States)

Author keywords

CD166; ezrin; KBA.62; melanoma; nestin; p Akt

Indexed keywords

BIOLOGICAL MARKER; EZRIN; NESTIN; NEVIRAPINE; PROTEIN CD166; PROTEIN KBA.62; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ARTICLE; DYSPLASTIC NEVUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOMA; NEVUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ANTIGENS, CD; CELL ADHESION MOLECULES, NEURONAL; CYTOSKELETAL PROTEINS; DIAGNOSIS, DIFFERENTIAL; FETAL PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERMEDIATE FILAMENT PROTEINS; MELANOMA; MELANOMA-SPECIFIC ANTIGENS; NERVE TISSUE PROTEINS; NEVUS; ONCOGENE PROTEIN V-AKT; SKIN NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 80053573523     PISSN: 01931091     EISSN: 15330311     Source Type: Journal    
DOI: 10.1097/DAD.0b013e318214ae8a     Document Type: Article

References (42)

1. Okun M, Kirkham N, Slater D, et al. What criteria reliably distinguish melanoma from benign melanocytic lesions? Histopathology. 2000;37: 464-472.
2. Cerroni L, Kerl H. Tutorial on melanocytic lesions. Am J Dermatopathol. 2001;23:237-241. (Pubitemid 32525418)
3. Ohsie SJ, Sarantopoulos GP, Cochran AJ, et al. Immunohistochemical characteristics of melanoma. J Cutan Pathol. 2008;35:433-444. (Pubitemid 351519417)
4. Sujatha SEF, Johnson S, Bate J. Immunohistochemical analysis of cutaneous malignant melanoma: comparison of S-100 protein, HMB-45 monoclonal antibody and NKI/C3 monoclonal antibody. Pathology. 1994; 26:16.
5. Bishop PW, Menasce LP, Yates AJ, et al. An immunophenotypic survey of malignant melanomas. Histopathology. 1993;23:159.
6. Orchard GE. Comparison of immunohistochemical labeling of melanocyte differentiation antibodies melan-A, tyrosinase and HMB45 with NKIC3 and S100 protein in the evaluation of benign naevi and malignant melanoma. Histochem J. 2000;32:475.
7. Bastian BC, Olshen AB, LeBoit PE, et al. Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol. 2003;163:1765-1770. (Pubitemid 37310008)
8. Ilmonen S, Vaheri A, Asko-Selijavaara S, et al. Ezrin in primary cutaneous melanoma. Mod Pathol. 2005;18:503-510. (Pubitemid 40478113)
9. Kaufmann O, Koch S, Burghardt J, et al. Tyrosinase, Melan-A, and KBA62 as markers for the immunohistochemical identification of metastatic amelanotic melanomas on paraffin sections. Mod Pathol. 1998;11:740.
10. Dai DL, Martinka M, Li G. Prognostic significance of activated Akt expression in melanoma: a Clinicopathologic study of 292 cases. J Clin Oncol. 2005;23:1473-1482.
11. Klein WM, Wu BP, Zhao S, et al. Increased expression of stem cell markers in malignant melanoma. Mod Pathol. 2007;20:102-107. (Pubitemid 44967955)
12. Clarkson KS, Sturdgess IC, Molyneux AJ. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A). J Clin Pathol. 2001;54:196.
13. Sundram U, Harvell JD, Rouse RV, et al. Expression of the B-Cell proliferation marker MUM1 by melanocytic lesions and comparison with S100, gp100 (HMB45), and MelanA. Mod Pathol. 2003;16:802.
14. Jungbluth AA, Busam KJ, Gerald WL, et al. A103: an anti-Melan - A monoclonal antibody for the detection of malignant melanoma in paraffinembedded tissues. Am J Surg Pathol. 1998;22:595.
15. Fetsch PA, Marincola FM, Abati A. The new melanoma markers: MART- 1 and Melan-A (the NIH experience). Am J Surg Pathol. 1999;23:607.
16. Miettinen M, Fernandez M, Franssila K, et al. Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers. Am J Surg Pathol. 2001;25:205.
17. Granter SR, Weilbaecher KN, Quigley C, et al. Role for microphthalmia transcription factor in the diagnosis of metastatic malignant melanoma. Appl Immunohistochem Mol Morphol. 2002;10:47.
18. Busam KJ, Kucukgol D, Sato E, et al. Immunohistochemical analysis of novel monoclonal antibody PNL2 and comparison with other melanocyte differentiation markers. Am J Surg Pathol. 2005;29:400.
19. Jungbluth AA, Iversen K, Coplan K, et al. T311-an antityrosinase monoclonal antibody for the detection of melanocytic lesion in paraffin embedded tissues. Pathol Res Pract. 2000;196:235.
20. Boyle JL, Haupt HM, Stern JB, et al. Tyrosinase expression in malignant melanoma, desmoplastic melanoma, and peripheral nerve tumors: an immunohistochemical study. Arch Pathol Lab Med. 2002;126:816.
21. King R, Googe PB, Weilbacher KN, et al. Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic and nonmelanocytic tumors. Am J Surg Pathol. 2001;25:51.
22. Busam KJ, Iversen K, Coplan KC, et al. Analysis of microphthalmia transcription factor expression in normal tissues and tumors, and comparison of its expression with S-100 protein, gp100, and tyrosinase in desmoplastic malignant melanoma. Am J Surg Pathol. 2001;25:197.
23. Slominski A, Tobin D, Shibahara S, et al. Melanin pigmentation inmammalian skin and its hormonal regulation. Physiol Rev. 2004;84:1155-1228. (Pubitemid 39287950)
24. Slominski A, Wortsman J, Plonka PM, et al. Hair follicle pigmentation. J Invest Dermatol. 2005;124:13-21. (Pubitemid 40100943)
25. Grichnik JM, Burch JA, Schulteis RD, et al. Melanoma, a tumor based on a mutant stem cell? J Invest Dermatol. 2006;126:142-153. (Pubitemid 43336106)
26. Herlyn M. Human melanoma: development and progression. Cancer Metastasis Rev. 1990;9:101-112. (Pubitemid 20311827)
27. Clark WH Jr, Elder DE, Guerry D, et al. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol. 1984;15:1147-1165. (Pubitemid 15128121)
28. Ordonez NG, Xiaolong J, Hickey RC. Comparison of HMB-45 monoclonal antibody and S100 protein in the immunohistochemical diagnosis of melanoma. Am J Clin Pathol. 1988;90:385.
29. Kantrow SM, Boyd AS, Ellis DL, et al. Expression of activated Akt in benign nevi, Spitz nevi and melanomas. J Cutan Pathol. 2007;34:593-596. (Pubitemid 47063230)
30. Kocan P, Jurkovic I, Böö r A, et al. Immunohistochemical study of melanocytic differentiation antigens in cutaneous malignant melanoma. A comparison of six commercial antibodies and one non-commercial antibody in nodular melanoma, superficially spreading melanoma and lentigo maligna melanoma. Cesk Patol. 2004;40:50-56.
31. Cohen-Knafo E, Al Saati T, Aziza J, et al. Production and characterization of an antimelanoma monoclonal antibody KBA.62 using a new melanoma cell line reactive on paraffin wax embedded sections. J Clin Pathol. 1995; 48:826-831.
32. Pagès C, Rochaix P, al Saati T, et al. KBA.62: a useful marker for primary and metastatic melanomas. Hum Pathol. 2008;39:1136-1142.
33. Mäkitie T, Carpén O, Vaheri A, et al. Ezrin as a prognostic indicator and its relationship to tumor characteristics in uveal malignant melanoma. Invest Ophthalmol Vis Sci. 2001;42:2442-2449. (Pubitemid 32954846)
34. Lugini L, Lozupone F, Matarrese P, et al. Potent phagocytic activity discriminates metastatic and primary human malignant melanomas: a key role of Ezrin. Lab Invest. 2003;83:1555-1567. (Pubitemid 37424017)
35. Flørenes VA, Holm R, Myklebost, et al. Expression of the neuroectodermal intermediate filament nestin in human melanomas. Cancer Res. 1994;54:354-356. (Pubitemid 24053166)
36. Brychtova S, Fiuraskova M, Hlobiková A. Nestin expression in cutaneous melanomas and melanocytic nevi. J Cutan Pathol. 2006;34:370-375.
37. Ehrmann J, Kolář Z, Mokrý J. Nestin as a diagnostic and prognostic marker: immunohistochemical analysis of its expression in different tumours. J Clin Pathol. 2005;58:222-223. (Pubitemid 40193814)
38. Swart G, Lunter PC, van Kilsdonk J, et al. Activated leukocyte cell adhesion molecule (ALCAM/CD166): signaling at the divide of melanoma cell clustering and cell migration? Cancer Metastasis Rev. 2005;24:223-236. (Pubitemid 40922796)
39. van Kempen L, Meier F, Egeblad M, et al. Truncation of activated leukocyte cell adhesion molecule: a gateway to melanoma metastasis. J Invest Dermatol. 2004;122:1293-1301. (Pubitemid 38651106)
40. van Kempen LC, van den Oord JJ, van Muijen GN, et al. Activated leukocyte cell adhesion molecule/CD 166 a marker of tumor progression in primary malignant melanoma of the skin. Am J Pathol. 2000;156:769-774. (Pubitemid 30626933)
41. Degen WGJ, van Kempen LCLT, Gijzen EGA, et al. MEMD, a new cell adhesion molecule in metastasizing human melanoma cell lines, is identical to ALCAM (activated leukocyte cell adhesion molecule). Am J Pathol. 1998;152:805-813. (Pubitemid 28110727)
42. Bernaba BN, Vogiatzis IP, Binder SW, et al. Potentially useful markers for desmoplastic melanoma: an analysis of KBA.62, p-AKT, and Ezrin. Am J Dermatopathol. 2011. In press.